compounding semaglutide fda enforcement news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our What Are the FDA's Key

Clinical studies suggest that the medication promotes significant weight loss and is well tolerated among individuals

American Med Spa Association.

Lilly's triple agonist retatrutide delivered weight loss of up to 28.7% in adults with obesity

they can also improve metabolic health by lowering inflammation in the body and boosting weight loss, which can make it easier to manage the condition

Key points include salt forms, delivery and dosing differences, known risks and contraindications, and how telehealth evaluation and follow up verify product quality, manage side effects, and track results

The GIP receptor activation facilitates glucose-dependent insulin release and plays a critical role in lipid metabolism, helping reduce fat deposition and improve overall energy balance